EAT
0.02
900%
XST
0.03
-40%
PIL
0.006
200%
HYD
0.014
-39.1%
TRI
0.031
158.3%
ENT
0.006
-33.3%
AGD
0.115
144.7%
ELS
1.345
-32.8%
CUF
0.04
135.3%
EOS
5.39
-29.9%
HWK
0.035
105.9%
EQS
0.012
-29.4%
AYM
0.006
100%
ERD
1.7
-29.2%
SKN
0.006
100%
T3D
0.085
-29.2%
NVA
1.535
98.1%
DTM
0.005
-28.6%
RML
0.086
91.1%
SPQ
0.01
-28.6%
CNJ
0.013
85.7%
1MC
0.05
-26.5%
RDN
0.009
80%
ATC
0.04
-25.9%
EUR
0.465
78.8%
DTR
0.4
-25.2%
RAU
0.31
72.2%
MTB
0.012
-25%
BIT
0.005
66.7%
RNX
0.006
-25%
RLC
0.005
66.7%
TEG
0.003
-25%
AON
0.013
62.5%
CDR
0.022
-24.1%
AMX
0.3
53.8%
DRO
4.59
-23.9%
BMG
0.023
53.3%
SLM
0.061
-23.8%
CAE
0.064
52.4%
PSL
0.032
-23.8%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

AGN on track for Phase 2 trials during CY24

Argenica Therapeutics (ASX:AGN) has completed the manufacturing of the ARG-007 drug required for Phase 2 clinical trials. The finalised, sterile drug product manufacturing will be completed by the end of the year keeping the Argenica on track for first patient dosing during Q1 CY24 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231214/pdf/05yjzbqmnd1b00.pdf $AGN #Phase2 #ClinicalTrials #shorts